EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Harnessing Quantitative Medicine to Advance Oncology Drug Development

Benjamin Wu, Kenta Yoshida iD, Pascal Chanu, Chunze Li

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70733 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Benjamin Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Drug Development, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncology drug development continues to have a high attrition rate despite major advances in therapeutic modalities such as antibody‐drug conjugates, bispecific antibodies, cell therapies, and cancer vaccines. Critical development decisions are often made under substantial uncertainty, creating a need for quantitative approaches that integrate diverse sources of evidence. Quantitative medicine (QM) and model‐informed drug development (MIDD) provide a framework to support decision‐making throughout the oncology drug development lifecycle by leveraging pharmacology, disease biology, clinical data, biomarkers, and computational modeling. This review highlights three potential applications of QM that address drug development challenges. First, tumor growth inhibition–overall survival (TGI‐OS) modeling links longitudinal tumor dynamics with survival outcomes, enabling earlier assessment of treatment benefit and supporting Phase III go/no‐go decisions using Phase Ib/II data. Second, pan‐molecule modeling across multiple antibody‐drug conjugates that share a common linker‐payload construct. This QM approach characterizes the class‐specific exposure–toxicity relationships and informs dose optimization strategies, as illustrated by peripheral neuropathy risk modeling for vc‐MMAE‐containing agents. Third, population pharmacokinetic modeling and clinical trial simulation can facilitate intravenous‐to‐subcutaneous bridging by predicting pharmacokinetic non‐inferiority, optimizing dose selection, and reducing development risk, as demonstrated for pertuzumab/trastuzumab and atezolizumab. Collectively, these examples demonstrate how QM can improve confidence in critical development decisions, optimize benefit–risk assessment, and enhance development efficiency. Continued integration of quantitative approaches, including emerging artificial intelligence and mechanistic modeling methodologies, has the potential to improve the probability of success and accelerate the delivery of effective oncology therapies to patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentNeoplasmsAntineoplastic AgentsHumansImmunoconjugatesModels, Biological

Stichwörter der Autor:innen

modeling and simulationspharmacokineticsquantitative medicine

Substanzen

Antineoplastic AgentsImmunoconjugates

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.

ORCID-Profile: Kenta Yoshida

Zitieren

APA

Wu, B., Yoshida, K., Chanu, P., & Li, C. (2026). Harnessing Quantitative Medicine to Advance Oncology Drug Development. Clinical and Translational Science. https://doi.org/10.1111/cts.70733

Vancouver

Wu B, Yoshida K, Chanu P, Li C. Harnessing Quantitative Medicine to Advance Oncology Drug Development. Clinical and Translational Science. 2026. doi:10.1111/cts.70733

BibTeX
@article{Wu2026,
  author = {Wu, Benjamin and Yoshida, Kenta and Chanu, Pascal and Li, Chunze},
  title = {Harnessing Quantitative Medicine to Advance Oncology Drug Development},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70733}
}
Kostenlos starten →